SCHEMBL3964418

SCHEMBL3964418

NC(CCO)c1cccc(OCCCCCOCc2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
CFD P00746 1/20 0.47
TPSB2 P20231 1/20 0.47
CYP4F2 P78329 1/20 0.43
CYP4A11 Q02928 1/20 0.43
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NR4A2 P43354 1/20 0.39
RRM1 P23921 1/20 0.39
MAOB P27338 1/20 0.39
PLA2G4B P0C869 1/20 0.39
ADRB2 P07550 1/20 0.39
ADRB1 P08588 1/20 0.39
ADRB3 P13945 1/20 0.39
GBA1 P04062 1/20 0.38
UGCG Q16739 1/20 0.38
GBA2 Q9HCG7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3969178 0.99 SMN1; SMN2 (0.54) KMT2ASMN1; SMN2CFDTPSB2CYP4F2
SCHEMBL15137119 0.96 KMT2A (0.54) KMT2ASMN1; SMN2CFDTPSB2CYP4F2
SCHEMBL3964184 0.93 KMT2A (0.55) KMT2ASMN1; SMN2CFDTPSB2CYP4F2
SCHEMBL3972720 0.86 SMN1; SMN2 (0.69) KMT2ASMN1; SMN2CFDTPSB2CYP4F2
SCHEMBL29818949 0.85 KMT2A (0.52) KMT2ASMN1; SMN2TDP1L3MBTL1MAOB
SCHEMBL3966532 0.84 KMT2A (0.52) KMT2ASMN1; SMN2CFDTPSB2CYP4F2
SCHEMBL2151185 0.82 ADRB2 (0.42) KMT2ASMN1; SMN2CFDTPSB2RRM1
SCHEMBL3972169 0.82 SMN1; SMN2 (0.45) KMT2ASMN1; SMN2CFDTPSB2
SCHEMBL2208049 0.81 KMT2A (0.44) KMT2ASMN1; SMN2ADRB2ADRB1ADRB3
SCHEMBL29818987 0.81 KMT2A (0.44) KMT2ASMN1; SMN2ADRB2ADRB1ADRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10188615-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2019-01-29 US disclosed
US-20180177746-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2018-06-28 US disclosed
EP-2091955-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT Acucela, Inc. (US) 2009-08-26 EP disclosed
WO-2009045479-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. (US) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10188615-B2 Alkoxy compounds for disease treatment ALDH1A2, CLN6, AGER KMT2A 3103/4885SMN1; SMN2 42/4885CFD 416/4885
US-20180177746-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ALDH1A2, CLN6, AGER KMT2A 3103/4885SMN1; SMN2 42/4885CFD 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.